Silexion Reports Positive Preclinical Findings for SIL204 in KRAS-Mutated Pancreatic Cancer
- Preclinical Study Results: Silexion Therapeutics announced that its study on KRAS-mutated pancreatic cancer cells showed that SIL204 significantly increased surface expression of major histocompatibility complex class I (MHC-I), suggesting enhanced tumor recognition by immune cells, which could improve treatment outcomes.
- Immunotherapy Potential: The findings indicate that SIL204 may not only exhibit direct anti-tumor activity but also influence biological pathways that allow tumors to evade immune surveillance, thereby potentially increasing the efficacy of immunotherapy, particularly in the context of pancreatic cancer's strong immune resistance.
- KRAS Signaling and Immune Evasion: Research highlights that oncogenic KRAS signaling is linked to impaired antigen presentation; by increasing MHC-I expression, SIL204 may reverse this immune evasion mechanism, supporting future therapeutic strategies involving PD-1/PD-L1 blockade.
- Clinical Trial Plans: Silexion is advancing clinical trials for SIL204 in Israel and the European Union, aiming to further validate its potential in treating locally advanced pancreatic cancer, demonstrating the company's strategic commitment to oncology advancements.
Trade with 70% Backtested Accuracy
Analyst Views on SLXN
About SLXN
About the author
Silexion Reports Positive Preclinical Findings for SIL204 in KRAS-Mutated Pancreatic Cancer
- Preclinical Study Results: Silexion Therapeutics announced that its study on KRAS-mutated pancreatic cancer cells showed that SIL204 significantly increased surface expression of major histocompatibility complex class I (MHC-I), suggesting enhanced tumor recognition by immune cells, which could improve treatment outcomes.
- Immunotherapy Potential: The findings indicate that SIL204 may not only exhibit direct anti-tumor activity but also influence biological pathways that allow tumors to evade immune surveillance, thereby potentially increasing the efficacy of immunotherapy, particularly in the context of pancreatic cancer's strong immune resistance.
- KRAS Signaling and Immune Evasion: Research highlights that oncogenic KRAS signaling is linked to impaired antigen presentation; by increasing MHC-I expression, SIL204 may reverse this immune evasion mechanism, supporting future therapeutic strategies involving PD-1/PD-L1 blockade.
- Clinical Trial Plans: Silexion is advancing clinical trials for SIL204 in Israel and the European Union, aiming to further validate its potential in treating locally advanced pancreatic cancer, demonstrating the company's strategic commitment to oncology advancements.
Silexion Therapeutics Reports Q4 Net Loss Increase
- Increased Net Loss: Silexion Therapeutics reported a net loss of approximately $4.4 million for Q4 2025, up from about $1.7 million in Q4 2024, indicating challenges in cost management and revenue growth.
- Improved Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $6.0 million, a significant increase from $1.2 million in the same period of 2024, suggesting improvements in financing or operational efficiency that may support future growth.
- Financial Health Risks: Despite the increase in cash reserves, the ongoing net losses could undermine investor confidence, potentially impacting the company's future financing capabilities and market performance, necessitating a focus on restoring profitability.
- Market Outlook Uncertainty: With the widening losses and fluctuating financial status, Silexion Therapeutics must implement effective measures to enhance operational efficiency and diversify revenue streams to meet market competition and investor expectations.
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2
SIL204 Development: Silexion Therapeutics has completed toxicology studies for SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer, showing no systemic organ toxicity.
Therapeutic Potential: SIL204 has demonstrated significant inhibition of cancer cell growth in preclinical models and positive anti-tumor activity in pancreatic cancer, paving the way for regulatory submissions in Israel and Germany.
Clinical Trial Plans: The therapy is set to progress to a Phase 2/3 trial in Q2 2026, utilizing a unique regimen that combines intratumoral and systemic administration to evaluate safety and efficacy in patients with locally advanced pancreatic cancer.
Stock Performance: Silexion's stock has fluctuated between $2.13 and $63.45 over the past year, closing at $2.44, reflecting a 13.48% increase in recent trading.
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
- Successful Toxicology Studies: Silexion has completed dual-species toxicology studies for SIL204, confirming no systemic organ toxicity, which lays the groundwork for planned regulatory submissions in Israel and Germany, potentially accelerating clinical trial progress.
- Clinical Trial Timeline: The company is on track to initiate a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026, ensuring competitiveness and timely market entry in the oncology sector.
- Innovative Therapy Potential: SIL204, designed as a next-generation RNA interference therapy targeting mutant KRAS oncogenes, has demonstrated significant anti-tumor activity in vitro, indicating its substantial potential in treating aggressive cancers.
- Integrated Treatment Strategy: The company's approach combines both intratumoral and systemic administration, aiming to improve survival rates for patients suffering from high-mortality cancers that currently lack effective treatment options.
Silexion Therapeutics Meets Nasdaq Listing Standards Again
Regaining Compliance: Silexion Therapeutics has regained compliance with Nasdaq listing rules regarding minimum bid price and shareholders' equity, confirming a minimum bid price of $1.00 per share and $2.5 million in shareholders' equity.
Clinical Development Focus: The company is advancing towards Phase 2/3 clinical trials for its RNAi therapy SIL204, which has shown promising preclinical results in inhibiting KRAS-driven cancers, and is committed to developing innovative treatments for solid tumor cancers.
Silexion Therapeutics Stock Rises Following Encouraging Preclinical Results for Pancreatic Cancer
Stock Performance: Silexion Therapeutics Corp. (SLXN) stock rose 14.83% to $5.15 on Thursday, with a trading volume significantly higher than its average, following the release of promising preclinical data.
Preclinical Study Findings: New data shows that SIL204 effectively targets pancreatic cancer metastasis, demonstrating anti-tumor activity and significant reductions in tumor burden across multiple organs in a mouse model, supporting its potential for clinical trials.
Silexion Reports Positive Preclinical Findings for SIL204 in KRAS-Mutated Pancreatic Cancer
- Preclinical Study Results: Silexion Therapeutics announced that its study on KRAS-mutated pancreatic cancer cells showed that SIL204 significantly increased surface expression of major histocompatibility complex class I (MHC-I), suggesting enhanced tumor recognition by immune cells, which could improve treatment outcomes.
- Immunotherapy Potential: The findings indicate that SIL204 may not only exhibit direct anti-tumor activity but also influence biological pathways that allow tumors to evade immune surveillance, thereby potentially increasing the efficacy of immunotherapy, particularly in the context of pancreatic cancer's strong immune resistance.
- KRAS Signaling and Immune Evasion: Research highlights that oncogenic KRAS signaling is linked to impaired antigen presentation; by increasing MHC-I expression, SIL204 may reverse this immune evasion mechanism, supporting future therapeutic strategies involving PD-1/PD-L1 blockade.
- Clinical Trial Plans: Silexion is advancing clinical trials for SIL204 in Israel and the European Union, aiming to further validate its potential in treating locally advanced pancreatic cancer, demonstrating the company's strategic commitment to oncology advancements.
Silexion Therapeutics Reports Q4 Net Loss Increase
- Increased Net Loss: Silexion Therapeutics reported a net loss of approximately $4.4 million for Q4 2025, up from about $1.7 million in Q4 2024, indicating challenges in cost management and revenue growth.
- Improved Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $6.0 million, a significant increase from $1.2 million in the same period of 2024, suggesting improvements in financing or operational efficiency that may support future growth.
- Financial Health Risks: Despite the increase in cash reserves, the ongoing net losses could undermine investor confidence, potentially impacting the company's future financing capabilities and market performance, necessitating a focus on restoring profitability.
- Market Outlook Uncertainty: With the widening losses and fluctuating financial status, Silexion Therapeutics must implement effective measures to enhance operational efficiency and diversify revenue streams to meet market competition and investor expectations.
Silexion Finishes Toxicology Studies for SIL204; Phase 2/3 Trial for Pancreatic Cancer Set to Start in Q2
SIL204 Development: Silexion Therapeutics has completed toxicology studies for SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer, showing no systemic organ toxicity.
Therapeutic Potential: SIL204 has demonstrated significant inhibition of cancer cell growth in preclinical models and positive anti-tumor activity in pancreatic cancer, paving the way for regulatory submissions in Israel and Germany.
Clinical Trial Plans: The therapy is set to progress to a Phase 2/3 trial in Q2 2026, utilizing a unique regimen that combines intratumoral and systemic administration to evaluate safety and efficacy in patients with locally advanced pancreatic cancer.
Stock Performance: Silexion's stock has fluctuated between $2.13 and $63.45 over the past year, closing at $2.44, reflecting a 13.48% increase in recent trading.
Silexion Completes Toxicology Studies for SIL204, Plans Phase 2/3 Trial in 2026
- Successful Toxicology Studies: Silexion has completed dual-species toxicology studies for SIL204, confirming no systemic organ toxicity, which lays the groundwork for planned regulatory submissions in Israel and Germany, potentially accelerating clinical trial progress.
- Clinical Trial Timeline: The company is on track to initiate a Phase 2/3 clinical trial for locally advanced pancreatic cancer in Q2 2026, ensuring competitiveness and timely market entry in the oncology sector.
- Innovative Therapy Potential: SIL204, designed as a next-generation RNA interference therapy targeting mutant KRAS oncogenes, has demonstrated significant anti-tumor activity in vitro, indicating its substantial potential in treating aggressive cancers.
- Integrated Treatment Strategy: The company's approach combines both intratumoral and systemic administration, aiming to improve survival rates for patients suffering from high-mortality cancers that currently lack effective treatment options.
Silexion Therapeutics Meets Nasdaq Listing Standards Again
Regaining Compliance: Silexion Therapeutics has regained compliance with Nasdaq listing rules regarding minimum bid price and shareholders' equity, confirming a minimum bid price of $1.00 per share and $2.5 million in shareholders' equity.
Clinical Development Focus: The company is advancing towards Phase 2/3 clinical trials for its RNAi therapy SIL204, which has shown promising preclinical results in inhibiting KRAS-driven cancers, and is committed to developing innovative treatments for solid tumor cancers.
Silexion Therapeutics Stock Rises Following Encouraging Preclinical Results for Pancreatic Cancer
Stock Performance: Silexion Therapeutics Corp. (SLXN) stock rose 14.83% to $5.15 on Thursday, with a trading volume significantly higher than its average, following the release of promising preclinical data.
Preclinical Study Findings: New data shows that SIL204 effectively targets pancreatic cancer metastasis, demonstrating anti-tumor activity and significant reductions in tumor burden across multiple organs in a mouse model, supporting its potential for clinical trials.
